AI Science Tracker

Delphi-2M forecasts the risk of more than 1,000 diseases

German Cancer Research Centre DKFZ; EMBL-EBI; University of Copenhagen · 17 Sep 2025 · medicine

Discovery

Delphi-2M forecasts the risk of more than 1,000 diseases

The September 2025 Nature version reports a GPT-style transformer trained on about 0.4 million UK Biobank participants and evaluated without retraining on 1.9 million Danish individuals. It models rates for more than 1,000 diseases and generates potential health trajectories up to 20 years ahead. This is retrospective risk modelling, with training-population biases; it does not establish a clinical benefit. The work also has a medRxiv preprint first indexed in June 2024.

Technology: Delphi-2M (GPT-style generative transformer)

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: retrospective or benchmark
  • Tested: Existing-record predictions in UK Biobank and Danish registries.
  • Still unknown: Not assessed: supplementary analyses and clinical deployment; population biases are discussed in the paper.
  • AI role: A modified generative transformer models disease events and timing.

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC12589094/ · https://pmc.ncbi.nlm.nih.gov/articles/PMC12657216/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 161 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.